Asset Details
Do you wish to reserve the book?
Update on the Epidemiology, Diagnosis, and Treatment of Mania in Older-Age Bipolar Disorder
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Update on the Epidemiology, Diagnosis, and Treatment of Mania in Older-Age Bipolar Disorder
Do you wish to request the book?
Update on the Epidemiology, Diagnosis, and Treatment of Mania in Older-Age Bipolar Disorder
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Update on the Epidemiology, Diagnosis, and Treatment of Mania in Older-Age Bipolar Disorder
2017
Overview
Purpose of Review
The population over age 60 is growing more rapidly than the general population. Given the projected increase and need for data that can inform treatment, this review provides a brief description of newer publications focused on mania in older-age bipolar disorder (OABD), including epidemiology, diagnosis, and treatments.
Recent Findings
Age cutoffs to define OABD range from 50 to 65 years. OABD clinical presentation and course of illness is highly variable, often characterized by mood episode recurrence, medical comorbidity, cognitive deficits, and impaired functioning. There is little pharmacotherapy data on mania in OABD. Lithium and valproate have been tested in a single randomized controlled trial and there is data of more limited quality with other compounds.
Summary
Treating OABD is challenging due to medical complexity, comorbidity, diminished tolerance to treatment, and a limited evidence base. More data is needed to keep pace with clinical demand.
Publisher
Springer US,Springer Nature B.V
